Athyrium raises $2B for debt/equity fund; Amgen teams with Carmot on Parkinson's; Neuralstem soars on failed study(?)
→ New York-based Athyrium Capital Management has closed on a new $2 billion healthcare fund to support some expanded work in the biopharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
